RecruitingPrimary Open Angle Glaucoma

Hydrus® Microstent New Enrollment Post-Approval Study

Eligible age

45+ yrs

Accepts

All genders

Locations

15 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.

Sponsor: Alcon Research

You may qualify if…

✓ An operable, age-related cataract with best corrected visual acuity (BCVA) of 20/40 or worse;
✓ Diagnosis of primary open angle glaucoma treated with no more than 4 topical hypotensive medications;
✓ Optic nerve appearance characteristic of glaucoma;
✓ Medicated IOP less than or equal to 31 millimeters mercury (mmHg); Other protocol-defined inclusion criteria may apply.

You may not qualify if…

✕ Closed angle forms of glaucoma;
✕ Congenital or developmental glaucoma;
✕ Secondary glaucoma;
✕ Use of more than 4 ocular hypotensive medications;
✕ Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior filtration or cilioablative surgery;
✕ Prior surgery with implanted device or other surgery involving the trabecular meshwork or Schlemm's canal;
✕ Other protocol-defined exclusion criteria may apply.